Early Response Assessment in Diffuse Large B-Cell Lymphoma (DLCL) Patients by 18-fluoro-2-deoxyglycose Positron Emission Tomography (FDG-PET)



Status:Completed
Conditions:Lymphoma
Therapuetic Areas:Oncology
Healthy:No
Age Range:18 - Any
Updated:5/30/2018
Start Date:May 2008
End Date:December 8, 2012

Use our guide to learn which trials are right for you!

Trial Summary
Trial Overview
Inclusion Criteria

Early Response Assessment in Patients With Diffuse Large B-cell Lymphoma Using 18-fluoro-2-deoxyglycose Positron Emission Tomography (FDG-PET)

Newly diagnosed DLCL patients will have baselne FDG-PET as part of initial staging (PET-1).
Patients will then undergo 2 cycles of chemotherapy with R/CHOP. 14 to 21 days following
cycle 2 of R/CHOP, patients will undergo repeat FDG-PET scan (PET-2). They will then complete
therapy as planned. Following completion of therapy, standard response assessment will be
performed, including CT scans of the chest, abdomen and pelvis and FDG-PET scan (PET-3).


Inclusion Criteria:

- Patients must have histologically or cytologically confirmed diagnosis of CD20+
diffuse large B cell lymphoma (LBCL) of any stage, including subtypes mediastinal
large B cell, centroblastic, immunoblastic, T cell rich B cell and anaplastic B cell
lymphoma

- Patients must have received no prior anti-lymphoma therapy.

- Age >18 years.

- Patients must have a treatment plan to include R/CHOP or R/CHOP followed by
radiotherapy.

- Ability to understand and the willingness to sign a written informed consent document.

Exclusion Criteria:

- Patients who have known HIV infection.

- Patients who are, in the opinion of their treating oncologist, unable to undergo
R/CHOP chemotherapy.
We found this trial at
1
site
Weill-Cornell Medical College
New York, New York 10021
?
mi
from
New York, NY
Click here to add this to my saved trials